
- Volume 0 0
Cancer Drug Targets Specific Cells
GlaxoSmithKline's phase 2 clinical trialof the investigational drug MAGE-A3Antigen Specific Cancer Immunotherapeutic(ASCI) for the treatment ofnon-small-cell lung cancer (NSCLC)showed a reduction in cancer recurrencefollowing surgery, when compared withplacebo. In the trial, all patients hadtumors that expressed a tumor-specificantigen—MAGE-A3—seen in 35% to 50%of early NSCLC. The multicenter, randomized,double-blind, placebo-controlledtrial included 182 patients receiving eitherMAGE-A3 ASCI or placebo. Relapseoccurred in 30.3% of patients in theMAGE-A3 group, compared with 41.7% ofpatients in the placebo group. This newcancer immunotherapy resulted in a 33%reduction of risk. Phase 3 clinical trials areset for early 2007. Trial results were presentedat the American Society of ClinicalOncology's annual meeting in Atlanta, Ga.
Ms. Farley is a freelance medicalwriter based in Wakefield, RI.
Articles in this issue
over 20 years ago
Questions and Answers About Dry Mouthover 20 years ago
Kidney Stoneover 20 years ago
Rx Productsover 20 years ago
can you READ these Rxs?over 20 years ago
OTC Productsover 20 years ago
Discrimination in Design of an Rx Drug Insurance Program?over 20 years ago
compounding HOTLINEover 20 years ago
A Calming Influence: An Analysis of ADHD Treatmentsover 20 years ago
Carbinoxamine Products Still Within Reachover 20 years ago
Wal-Mart Pharmacist of the Year: Indispensable to Her CommunityRelated to this article








